A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for the treatment of adolescent (12-17 years of age) and adult (18-75 years of age) subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy.
- IRB Number: 1811258547
- Research Study Identifier: TX10342
- Principal Investigator: Matthew Turner, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required